US Drug Discovery Informatics Market Reaches $1,466.8 Million in 2025 with 8.3% CAGR

US drug discovery informatics market was valued at $1,466.8 million in 2025 and is projected to reach $3,252.3 million by 2035, growing at a CAGR of 8.3% during the forecast period (2026–2035). Drug discovery informatics in the United States encompasses the use of advanced computational modeling, data analytics, and integrated informatics platforms to support critical stages of drug development, including virtual screening, molecular docking, structure-based drug design, sequencing and target data analysis, and library and database management. The market is experiencing strong and sustained growth, driven by the dominance of the U.S. pharmaceutical and biotechnology industry, high R&D expenditure, and early adoption of artificial intelligence, machine learning, and cloud-based technologies. The presence of leading pharmaceutical companies, innovative biotech startups, top-tier academic research institutions, and a robust network of contract research organizations (CROs) continues to reinforce the country’s leadership in data-driven drug discovery. Key trends shaping the U.S. drug discovery informatics landscape include the extensive integration of AI and machine learning to accelerate hit identification and lead optimization, growing reliance on cloud and high-performance computing environments, and increased utilization of large-scale chemical, biological, genomic, and real-world datasets to improve efficiency and reduce drug development timelines.

Browse the full report description of “US Drug Discovery Informatics Market Size, Share & Trends Analysis Report by Function (Docking, Molecular Modeling, Libraries & Database Preparation, Sequencing & Target Data Analysis, and Others), By End-User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Others), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/us-drug-discovery-informatics-market

According to NCBI, NIH, the National Library of Medicine (NLM), the National Science Foundation (NSF), and the U.S. Food and Drug Administration (FDA), the US continues to lead globally in drug discovery informatics through large-scale federal investments, extensive use of high-performance computing, and dominance in public biomedical data generation and usage.

Key Innovators Driving US Drug Discovery Informatics Transformation

The key players in the US drug discovery informatics market include Agilent Technologies, Inc, Illumina, Inc., PerkinElmer, Inc., Schrödinger, Inc, Thermo Fisher Scientific Inc., among others. These companies are advancing the market through AI-enabled modeling and simulation platforms, integrated end-to-end informatics solutions, and scalable cloud-based technologies, shaping the future of drug discovery and pharmaceutical innovation in the US.

• In October 2025, Nabla Bio expanded its collaboration with Takeda Pharmaceutical, utilizing Nabla’s AI-driven Joint Atomic Model (JAM) platform to design protein-based therapeutics. The agreement reportedly includes upfront payments and milestone-based opportunities exceeding $1 billion, reflecting strong industry confidence in AI-enabled biologics discovery.
• in October 2025, Eli Lilly and Company announced a partnership with NVIDIA to deploy a high-performance AI supercomputer, the DGX SuperPOD, to accelerate drug discovery and development. The initiative highlights growing investment in advanced computational infrastructure to enhance molecular simulations, screening processes, and data analytics

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Function
  • By End-Users
• Competitive Landscape - Agilent Technologies, Inc, Illumina, Inc., PerkinElmer, Inc., Schrödinger, Inc, Thermo Fisher Scientific Inc., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

US Drug Discovery Informatics Market Report Segment

By Function

• Docking
• Molecular Modeling
• Libraries & Database Preparation
• Sequencing & Target Data Analysis
• Others

By End-Users

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Others

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/us-drug-discovery-informatics-market